CMR Surgical
The unicorn company’s small robot offers portability and unique design features that enable surgeons worldwide to provide minimal access surgery (MAS) to more people and across more specialities, such as thoracic surgery.
Over 75 per cent of hospitals that perform surgeries with Versius now use the system across at least two specialities, which has increased adoption uptake. Versius’s small V-wristed instruments and 3D HD vision support precise and accurate surgical performance across common- and complex elective procedures.
The robotic system biomimics the human arm with benefits such as optimised port placement, fully-wristed instruments that enhance dexterity and accuracy, and multiple ergonomic working positions — all of which can help reduce surgeons’ stress and fatigue and improve overall surgical efficacy. In 2023, CMR Surgical achieved over 50 per cent growth in its global install base.
In October 2024, CMR Surgical secured FDA approval for Versius in the US market. It now seeks to address the strong demand for surgical robotics across key territories including Asia Pacific, the Middle East and Africa, to help patients access optimal surgical care. CMR boasts the only global surgical robotics manufacturing facility in the UK.
